SCHEMBL22729341

SCHEMBL22729341

CCN(CC)CCNC(=O)C(C)(C)NC(=O)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.46
SIRT2 Q8IXJ6 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
SIRT3 Q9NTG7 1/20 0.44
HTT P42858 1/20 0.43
SYK P43405 1/20 0.43
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TGM2 P21980 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17371252 0.88 MEN1 (0.49) CTSSSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL29861096 0.86 SMN1; SMN2 (0.50) CTSSSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4187465 0.84 SMN1; SMN2 (0.50) CTSSSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL21222698 0.83 HTT (0.49) CTSSSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL2189201 0.80 SMN1; SMN2 (0.48) CTSSSIRT2SMN1; SMN2LMNAMEN1
SCHEMBL29813445 0.80 CTSS (0.51) CTSSSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL6762393 0.79 SYK (0.54) CTSSSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL8427919 0.78 MEN1 (0.53) CTSSSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL14151477 0.78 CTSS (0.49) CTSSSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL21172170 0.77 HTT (0.63) SIRT2SMN1; SMN2LMNASIRT1SIRT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111630058-B Glucopyranosyl derivative and use thereof 广东东阳光药业有限公司 2022-02-15 CN disclosed
US-11186602-B2 Glucopyranosyl derivative and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-11-30 US disclosed
US-20210054013-A1 GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-02-25 US disclosed
EP-3747892-A1 GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2020-12-09 EP disclosed
CN-111630058-A Glucopyranosyl derivative and use thereof 广东东阳光药业有限公司 2020-09-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11186602-B2 Glucopyranosyl derivative and use thereof SLC5A1, SLC5A2, UGGT1 CTSS 3368/4885SIRT2 1167/4885SMN1; SMN2 3620/4885
US-20210054013-A1 GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF SLC5A1, SLC5A2, UGGT1 CTSS 3368/4885SIRT2 1167/4885SMN1; SMN2 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.